NHS to fund drug that prolongs lives of children with muscle-wasting disease Spinraza to be made available to spinal muscular atrophy patients
A drug that could prolong the lives of children with a rare muscle-wasting disease has been approved by the NHS in England after lengthy negotiations with the manufacturer over the high price.
Spinraza could help between 600 and 1,200 children and adults in England and Wales who have the genetic condition spinal muscular atrophy (SMA). It affects the nerves in the spinal cord, making muscles weaker and causing problems with movement, breathing and swallowing. It can shorten the life expectancy of babies and toddlers. The Guardian
See also:
A drug that could prolong the lives of children with a rare muscle-wasting disease has been approved by the NHS in England after lengthy negotiations with the manufacturer over the high price.
Spinraza could help between 600 and 1,200 children and adults in England and Wales who have the genetic condition spinal muscular atrophy (SMA). It affects the nerves in the spinal cord, making muscles weaker and causing problems with movement, breathing and swallowing. It can shorten the life expectancy of babies and toddlers. The Guardian
See also:
- NHS England to fund first ever treatment for children with rare muscle-wasting condition NHS England
- Spinal muscular atrophy: Spinraza approval delights family BBC News
- NHS finally agrees a deal with pharmaceutical giant for a £450,000 'wonder drug' The Daily Mail
- First treatment available for spinal muscular atrophy OnMedica
No comments:
Post a Comment